STOCKS TELEGRAPH

Tag: NNOX stock

  • Nano-X (NNOX) Stock’s Value Doubles After Nvidia’s Stake Disclosure

    Nano-X (NNOX) Stock’s Value Doubles After Nvidia’s Stake Disclosure

    The value of NNOX’s shares increased dramatically on Thursday following Nvidia’s announcement that it acquired a stake in Nano-X Imaging Ltd (NASDAQ: NNOX). Nano-X’s stock price further increased 36.32% to $12.95 during Friday’s trading session, indicating a notable boost in investor confidence and interest in the company’s future prospects. The rise on US stock charts translated into Nano-X’s market value more than doubling within two days.

    Another recent accomplishment further reinforces Nano-x’s positive outlook as its subsidiary Nanox AI Ltd. was granted FDA clearance under 510(k) for HealthFLD. In addition to streamlining the qualitative and quantitative analysis of liver attenuation from CT scans, this AI software caters specifically to patients aged 18 to 75.

    HealthFLD aims to aid clinicians in the detection of fatty liver, a precursor to metabolic dysfunction-associated steatotic liver disease (MASLD), a condition prevalent among a substantial portion of the U.S. adult population. MASLD, commonly associated with obesity, cardiovascular disease, and type 2 diabetes, poses significant public health challenges.

    The traditional difficulty in accurately assessing liver attenuation on contrast-enhanced scans has limited clinicians’ ability to detect non-severe cases of MASLD. HealthFLD addresses this gap by offering a reliable, non-invasive solution to support early detection and intervention, potentially improving health outcomes for affected individuals.

    Nano-X emphasizes the importance of HealthFLD as the third product in Nanox AI’s suite of AI-powered population health solutions, designed to combat chronic diseases and potentially improve health outcomes. The company believes that innovative AI solutions like HealthFLD could provide substantial benefits to the biopharmaceutical industry by streamlining the identification of candidates for clinical trials of therapies for liver diseases, including MASLD.

    This FDA clearance marks the third product in Nanox AI’s suite of population health solutions to receive regulatory approval, following HealthCCSng, a solution for detecting coronary artery calcium, and HealthOST, a solution for assessing vertebral compression fractures and bone mineral density. Nano-X sees these regulatory milestones as solidifying its position as a leading developer of automated AI software medical devices.

  • Nanox Imaging Reports Surge After FDA Clearance for AI Software

    Nanox Imaging Ltd. (NASDAQ: NNOX) experienced a notable surge in its stock price today, following a robust trading day with a 6% climb and an even more remarkable 83% after-hours performance. The surge occurred subsequent to the company obtaining FDA clearance for its HealthFLD artificial intelligence (AI) software.

    Unlocking HealthFLD’s Potential

    This surge coincides with NNOX receiving 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its HealthFLD AI software. HealthFLD is tailored to provide automated qualitative and quantitative analysis of liver attenuation from routine chest and abdomen CT scans. This aids clinicians in identifying fatty liver, a significant indicator of metabolic dysfunction-associated steatotic liver disease (MASLD).

    Addressing an Ongoing Health Issue

    MASLD, formerly known as non-alcoholic fatty liver disease (NAFLD), affects around 24% of U.S. adults and is closely linked with obesity, cardiovascular disease, and type 2 diabetes. Timely diagnosis of MASLD is critical, as it can lead to severe liver complications if left untreated.

    Future Outlook and Collaborative Efforts

    The FDA clearance for HealthFLD represents a significant advancement in non-invasive diagnostic tools for liver-related diseases. NNOX’s CEO, Erez Meltzer, highlighted HealthFLD’s potential to facilitate the identification of candidates for clinical trials, particularly for metabolic diseases like MASLD and metabolic dysfunction-associated steatohepatitis (MASH).

    Investor Confidence and Strategic Partnerships

    The FDA’s endorsement underscores Nanox’s dedication to developing state-of-the-art AI solutions for population health management. HealthFLD’s clearance supplements Nanox’s existing suite of AI-powered solutions, including HealthCCSng and HealthOST.

    Moreover, the disclosure of Nvidia’s stake in NNOX has likely bolstered investor interest in the company.

    Conclusion

    The approval of HealthFLD represents a significant stride in combatting MASLD and related conditions. Nanox Imaging’s innovative technology holds promise for revolutionizing the diagnosis and management of liver diseases, offering potential improvements in patient outcomes and healthcare efficiency.

  • Why shares of Nano-X Imaging Ltd. (NNOX) surged in premarket?

    Nano-X Imaging Ltd. (NNOX) stock soared 62.93% at $67.34 in premarket trading hours on the last check Thursday. The stock of NNOX lost -0.29% to complete the last trading session at $41.33.

    Nano-X Imaging Ltd ‎(NNOX), an innovative medical imaging technology company which aims for mass deployment of cost reduced imaging systems, notified that its single-source Nanox. ARC digital x-ray technology has been given 510(k) Approval from the FDA, after which NNOX stock surged substantially. NANO-X is also expected to put forward another application for its multi-source Nanox Arcand the NanoxCloud, this year. If approved, the multisource NanoX ARC will be commercialized and sold globally.

    “Obtaining 510(k) clearance from the FDA for our single-source Nanox.ARC digital x-ray is a significant step forward along our US regulatory pathway,” Concluded Ran Poliakine, CEO Nanox.

    NNOX Distinctive Competency Over Its Peers

    NNOX, founded by Ran Poliakine, is an Israel based corporation manufacturing a commercial-grade digital X-ray source which will be immensely significant for improved affordable medical imaging.

    Nanoxplans for its unique technology to decrease the costs of medical imaging systems and aims for partnerships with several healthcare organizations for low cost, and an early detection medical imaging service. NNOX stock has aimed to finalize a minimum distribution of 15,000 Nanox ARC systems by the end of 2024.

    Conclusion

    NANO-X imaging has invested in a very lucrative market of Medical imaging especially amongst the time of a pandemic. NNOX stock has pioneered affordable quality medical imaging and approval by FDA may prove to be extremely significant in further diversifying their income stream and providing income stability as well as a financial surplus, with the company keen on producing results.

  • Pre-Market Cues: 32 Stocks Roaring for Change On December 1st

    Pre-Market Cues: 32 Stocks Roaring for Change On December 1st

    China Automotive Systems Inc. (CAAS) stock soared 2.38% to $10.75 in the pre-market trading after reporting that it shipped approximately 120,000 units from its portfolio of electric power steering products for use in Chinese electric vehicles during 2020. The most recent rating by Brean Murray, on August 15, 2011, is a Hold.
    Before the trading started on December 01, 2020, G1 Therapeutics Inc. (GTHX) is up 4.05% to reach $19.0. It has been trading in a 52-week range of $8.80 to $31.38.
    Sundial Growers Inc. (NASDAQ: SNDL) shares are trading up 29.83% at $0.947 at the time of writing following the announcement its elimination of senior secured second lien convertible notes. Company’s 52-week ranged between $0.14 to $3.88.
    Jaguar Health Inc. (JAGX) grew over 69.45% at $0.5929 in pre-market trading today.
    SuperCom Ltd. (SPCB) stock moved down -10.74 percent to $1.08 in the pre-market trading and the company recently declared that it has secured a contract to provide its PureSecurity Electronic Monitoring (EM) suite in Wisconsin.
    MicroStrategy Incorporated (NASDAQ: MSTR) shares are trading up 4.93% at $359.66 at the time of writing. Company’s 52-week ranged between $90.00 to $280.00. Analysts have a consensus price target of $200.
    Veritone Inc. (VERI) grew over 4.4% at $27.78 in pre-market trading today after announcing that it now supports NVIDIA CUDA for GPU-based AI and machine learning.
    Before the trading started on December 01, 2020, Creative Realities Inc. (CREX) is down -7.26% to reach $1.15. It has been trading in a 52-week range of $0.52 to $5.98.
    Moderna Inc. (MRNA) stock soared 10.32% to $168.5 in the pre-market trading after declaring that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis. The most recent rating by Wells Fargo, on November 23, 2020, is an Equal weight.
    VBI Vaccines Inc. (VBIV), a Biotechnology company, rose about 3.94% at $3.56 in pre-market trading Tuesday.
    Schultze Special Purpose Acquisition Corp. (SAMA) stock moved up 2.86 percent to $12.6 in the pre-market trading after reporting effectiveness of registration statement for proposed business combination with Clever Leaves International Inc.
    Celsion Corporation (CLSN) gained over 5.59% at $0.71 in pre-market trading Tuesday December 01, 2020.
    Nano-X Imaging Ltd. (NNOX) is up more than 5.22% at $64.5 in pre-market hours Tuesday December 01, 2020. The healthcare firm lately announced revised time of live demonstration at the 2020 radiology society of North America virtual annual meeting. The stock had jumped over 17.21% to $61.30 in the last trading session.
    Before the trading started on December 01, 2020, Greenlane Holdings Inc. (GNLN) is up 2.89% to reach $4.27. It has been trading in a 52-week range of $1.02 to $4.20.
    Mogo Inc. (MOGO) stock soared 3.77% to $2.75 in the pre-market trading. The firm recently declared the release of its new updated Mogo app featuring an interactive Rainforest Mode as part of the MogoCard experience. The most recent rating by Raymond James, on July 23, 2020, is an Outperform.
    Altimmune Inc. (NASDAQ: ALT) shares are trading up 9.57% at $13.4 at the time of writing. Company’s 52-week ranged between $1.60 to $35.10. Analysts have a consensus price target of $28.
    Novavax Inc. (NVAX) grew over 6.09% at $148.0 in pre-market trading today following publication its COVID-19 vaccine clinical development progress.
    Marathon Patent Group Inc. (MARA), a Capital Markets company, rose about 7.96% at $6.78 in pre-market trading Tuesday.
    Aphria Inc. (APHA) is up more than 3.46% at $8.67 in pre-market hours Tuesday December 01, 2020. The healthcare company recently revealed that it has closed the accretive, strategic acquisition of SW Brewing Company, LLC. The stock had jumped over 8.41% to $8.38 in the last trading session.
    AquaBounty Technologies Inc. (AQB) gained over 4.31% at $6.05 in pre-market trading Tuesday December 01, 2020.
    Before the trading started on December 01, 2020, ADMA Biologics Inc. (ADMA) is up 2.45% to reach $2.09 following the announcement its commencement of operations and initiation of collections at its newest ADMA BioCenters plasma collection facility located in Maryville, Tennessee. It has been trading in a 52-week range of $1.45 to $4.95.
    CureVac N.V. (CVAC) is down more than -3.12% at $101.89 in pre-market hours Tuesday December 01, 2020. The stock had jumped over 22.29% to $105.17 in the last trading session.
    OrganiGram Holdings Inc. (OGI) gained over 4.26% at $1.47 in pre-market trading Tuesday December 01, 2020 after releasing its results for the fourth quarter ended August 31, 2020.
    FuelCell Energy Inc. (FCEL) is down more than -3.43% at $9.85 in pre-market hours Tuesday December 01, 2020. The stock had jumped over 5.26% to $10.20 in the last trading session.
    SSR Mining Inc. (SSRM) grew over 2.12% at $18.8 in pre-market trading today. The company lately publicized that positive results of the Çöpler District master plan studies.
    Before the trading started on December 01, 2020, Entasis Therapeutics Holdings Inc. (ETTX) is up 4.35% to reach $1.92. It has been trading in a 52-week range of $1.58 to $5.64.
    Luokung Technology Corp. (LKCO) is up more than 2.93% at $0.6 in pre-market hours Tuesday December 01, 2020 after the firm reported that it won bid for Heilongjiang Institute of Technology (“HIT”) Smart Campus first phase procurement project of USD 1.3 million. The stock had jumped over 4.09% to $0.58 in the last trading session.
    Riot Blockchain Inc. (RIOT) is up more than 3.55% at $8.75 in pre-market hours Tuesday December 01, 2020. The stock had jumped over 35.20% to $8.45 in the last trading session.
    Before the trading started on December 01, 2020, Dada Nexus Limited (DADA) is down -4.28% to reach $55.47 after declaring proposed follow-on public offering of American depositary shares. It has been trading in a 52-week range of $14.60 to $56.91.
    Logitech International S.A. (NASDAQ: LOGI) shares are trading down -3.3% at $87.32 at the time of writing. Company’s 52-week ranged between $31.37 to $95.71.
    Advaxis Inc. (ADXS), a Biotechnology company, rose about 11.86% at $0.33 in pre-market trading Tuesday. The biotechnology firm recently declared closing of $9.2 million public offering.
    Arbutus Biopharma Corporation (NASDAQ: ABUS) shares are trading up 11.26% at $5.04 at the time of writing. Company’s 52-week ranged between $0.88 to $9.02. Analysts have a consensus price target of $8.

  • Why Nano-X Imaging Ltd. (NASDAQ: NNOX) Stock Soared?

    Why Nano-X Imaging Ltd. (NASDAQ: NNOX) Stock Soared?

    Shares of Nano-X Imaging Ltd. (NASDAQ: NNOX) were up 32.87% as it has announced a partnership with South-Korean chipmaker SK Hynix Inc. to build machines that changed the century-old X-ray industry. Nano-X Imaging aimed to transform the medical devices industry which used the same old technology since the discovery of X-rays in the late-19th century.

    Nano-X Limited uses semiconductors instead of metal filaments in its devices to generate X-rays. The partnership with the largest chipmaker SK Hynix has provided an opportunity to Nano-X to bring new technologies. Nano-X has devices that produce less radiation and are cheaper. Nano-X devices will be able to disrupt the traditional system as they cannot only reduce radiation, improve images but also provide access for more patients.

    Nano-X has earlier signed an exclusive distribution agreement with SPI Medical for the deployment and introduction of Nanox’s medical imaging services in Mexico. Nanox will offer the Nanox Systems to SPI for pilots in the public and private sectors. This company has a unique technology and has a strong business model.

    Nano-X Imaging (NASDAQ: NNOX) shares went up 32.87% as it gained +15.88 during the trading session of Friday. Nano-X Imaging share price went from a low point around $20.25 to briefly over $49.25 in the past 52 weeks, though shares have since pulled back to $64.19. Nano-X market cap has remained high, hitting $2.23 billion at the time of writing. It has moved up 216.91% and 30.34% from its 52-weeks low and 52-weeks high, respectively.

    Nanox has a solution that has the ability to revolutionize the medical devices industry. Its new technology could reduce the cost of medical imaging systems and is striving to work with many organizations and companies to provide affordable technologies to customers. As the world lack access to diagnostic imaging, it has aimed to supply 4,500 units in various countries. It has also decided to join forces with the Foxconn Technology group for the mass production. It has also submitted applications to FDA for the approval.

    Nano-X Imaging has a vision called 1x1x1 aimed at establishing enough systems globally that every person on the planet has access to at least one medical imaging scan each year. Nanox is scheduled to participate in two upcoming investor conferences including Cantor Virtual Global Healthcare Conference and Jefferies Asia Forum on September 15 and September 16, respectively.